| 冯 佳,许 斌,宋启斌.EGFR 19与21号外显子突变的晚期非小细胞肺癌一线TKI治疗疗效差异的研究进展[J].肿瘤学杂志,2016,22(3):167-171. |
| EGFR 19与21号外显子突变的晚期非小细胞肺癌一线TKI治疗疗效差异的研究进展 |
| Research Advance on Difference of Efficacy of First-line Tyrosine Kinase Inhibitor Treatment for Advanced Non-small Cell Lung Cancer Patients with Exon 19 and 21 EGFR Mutation |
| 投稿时间：2015-11-23 |
| DOI：10.11735/j.issn.1671-170X.2016.03.B002 |
|
 |
| 中文关键词: 表皮生长因子受体 基因突变 非小细胞肺癌 酪氨酸激酶抑制剂 疗效 外显子 |
| 英文关键词:epidermal growth factor receptor gene mutation non-small cell lung cancer tyrosine kinase inhibitor efficacy exon |
| 基金项目: |
|
| 摘要点击次数: 2747 |
| 全文下载次数: 944 |
| 中文摘要: |
| 摘 要：表皮生长因子受体（epidermal growth factor receptor，EGFR）19号外显子缺失和21号外显子的L858R点突变是非小细胞肺癌(non-small cell lung cancer，NSCLC)中最常见的EGFR突变类型，并且预示经EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）治疗给患者带来更优的生存获益。临床研究表明，这两种突变类型患者在EGFR-TKI治疗中的获益有差异。文章主要就EGFR 19与21号外显子突变的晚期NSCLC一线TKI治疗疗效差异的研究进展作一综述。 |
| 英文摘要: |
| Abstract：Exon 19 deletion and L858R point mutation of exon 21 in epidermal growth factor receptor(EGFR) are the most common EGFR mutations in non-small cell lung cancer (NSCLC)，and predict better survival benefit after treatment with EGFR-tyrosine kinase inhibitor(TKI). Some clinical studies have indicated difference of survival benefit between these two EGFR mutation types. This review focuses on the different treatment outcome after first-line TKI treatment for advanced NSCLC patients with exon 19 or 21 EGFR mutation patterns. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |